New drugs for breast cancer and multiple myeloma won approval from the Food and Drug Administration on Friday, expanding options for patients in advanced stages of those diseases. The breast cancer drug, Afinitor from Novartis , seems to expand the time that endocrine therapy can keep the disease...
FULL ARTICLE AT The New York Times